<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163057</url>
  </required_header>
  <id_info>
    <org_study_id>HPV-005</org_study_id>
    <nct_id>NCT02163057</nct_id>
  </id_info>
  <brief_title>Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>Prospective Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma (HNSCCa)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Inovio Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/IIa, open-label study to evaluate the safety, tolerability, and
      immunogenicity of INO-3112 DNA vaccine delivered by Electroporation to subjects with HPV
      associated head and neck squamous cell cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/IIa, open-label, study to evaluate the safety, tolerability, and
      immunogenicity of INO-3112 [6 mg of VGX-3100 (2 separate DNA plasmids respectively encoding
      E6 and E7 proteins of HPV 16 and HPV 18) and 1 mg of INO-9012 (DNA plasmid encoding human
      interleukin 12)] delivered by electroporation (EP) in up to 25 (twenty five) subjects with
      HPV positive head and neck cancer. The immunotherapy will be studied in following two groups
      of subjects:

        1. Subjects who will receive immunotherapy before and after definitive surgery (Cohort I)

        2. Subjects who will receive immunotherapy at least 2 months after chemoradiation therapy
           (Cohort II).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of INO-3112 (VGX-3100 and INO-9012) delivered via IM+EP</measure>
    <time_frame>6 months post last dose</time_frame>
    <description>Evaluate the safety and tolerability of immunotherapy with INO-3112 (VGX-3100 and INO-9012) when delivered intramuscularly followed by electroporation with CELLECTRA®-5P in patients with HPV associated Head and Neck Cancer.
Adverse events will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of INO-3112 (VGX-3100 and INO-9012) delivered via IM+EP</measure>
    <time_frame>6 months post last dose</time_frame>
    <description>Evaluate the cellular and humoral immune responses to immunotherapy with INO-3112 (VGX-3100 and INO-9012) delivered by electroporation with CELLECTRA®-5P in patients with HPV associated Head and Neck cancer
Measure HPV 16 and HPV 18 E6 E7 Ig levels, IFN-γ-secreting cells and cytotoxic T cells in response to HPV specific immunotherapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-tumor effects</measure>
    <time_frame>6 months post last dose</time_frame>
    <description>Anti-tumor effects by investigator's clinical assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months post last dose</time_frame>
    <description>Progression Free Survival</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Head and Neck Squamous Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Surgery Cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1.1 mL of INO-3112 (VGX-3100 and INO-9012) delivered IM via CELLECTRA-5P device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1.1 mL of INO-3112 (VGX-3100 and INO-9012) delivered IM via CELLECTRA-5P device</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered IM via EP with CELLECTRA-5P device</intervention_name>
    <description>Eligible subjects who consent to participate in the study will receive a 1.1 mL IM injection of INO-3112 (VGX-3100 and INO-9012) via IM+EP with CELLECTRA®-5P. All subjects will receive a total of 4 doses of immunotherapy</description>
    <arm_group_label>Surgery Cohort</arm_group_label>
    <arm_group_label>Chemoradiation</arm_group_label>
    <other_name>VGX-3100</other_name>
    <other_name>INO-9012</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated written Ethics Committee approved informed consent.

          2. Age ≥18 years.

          3. Histologically confirmed HPV-positive (as assessed by p16 IHC or oncogenic HPV ISH or
             PCR) mucosal squamous cell head and neck cancer:

               -  For pre-surgical subjects, p16 positivity must be confimed prior to first dose

               -  For subjects post-chemoradiation, HPV 16 and HPV 18 positivity must be confirmed
                  prior to first dose.

          4. Adequate bone marrow, hepatic, and renal function. ANC (Absolute Neutrophil Count) ≥
             1.5x109 cell/ml, platelets ≥75,000 cells/mm3, hemoglobin ≥9.0 g/dL, concentrations of
             total serum bilirubin within 1.5 x upper limit of normal (ULN), AST, ALT within 2.5x
             institutional ULN, CPK within 2.5 x ULN.

          5. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1.

        Exclusion Criteria:

          1. Anticipated concomitant immunosuppressive therapy (excluding non-systemic inhaled,
             topical skin and/or eye drop-containing corticosteroids).

          2. Any concurrent condition requiring the continued use of systemic steroids (&gt;10 mg
             prednisone or equivalent per day) or the use of immunosuppressive agents. All other
             corticosteroids must be discontinued at least 4 weeks prior to Day 0 of treatment.

          3. Administration of any vaccine within 6 weeks of enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ildiko Csiki, MD</last_name>
    <role>Study Director</role>
    <affiliation>Inovio Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.inovio.com</url>
    <description>Sponsor's Website</description>
  </link>
  <reference>
    <citation>Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, Knott C, Lin F, Boyer JD, Draghia-Akli R, White CJ, Kim JJ, Weiner DB, Sardesai NY. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012 Oct 10;4(155):155ra138. doi: 10.1126/scitranslmed.3004414.</citation>
    <PMID>23052295</PMID>
  </reference>
  <reference>
    <citation>Diehl MC, Lee JC, Daniels SE, Tebas P, Khan AS, Giffear M, Sardesai NY, Bagarazzi ML. Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother. 2013 Oct;9(10):2246-52. doi: 10.4161/hv.24702. Epub 2013 Jun 4.</citation>
    <PMID>24051434</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <disposition_first_submitted>March 6, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 6, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 7, 2018</disposition_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and neck squamous cell cancer</keyword>
  <keyword>Papillomavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

